Cargando…

Alzheimer's early detection in post-acute COVID-19 syndrome: a systematic review and expert consensus on preclinical assessments

INTRODUCTION: The risk of developing Alzheimer's disease (AD) in older adults increasingly is being discussed in the literature on Post-Acute COVID-19 Syndrome (PACS). Remote digital Assessments for Preclinical AD (RAPAs) are becoming more important in screening for early AD, and should always...

Descripción completa

Detalles Bibliográficos
Autores principales: Vandersteen, Clair, Plonka, Alexandra, Manera, Valeria, Sawchuk, Kim, Lafontaine, Constance, Galery, Kevin, Rouaud, Olivier, Bengaied, Nouha, Launay, Cyrille, Guérin, Olivier, Robert, Philippe, Allali, Gilles, Beauchet, Olivier, Gros, Auriane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320294/
https://www.ncbi.nlm.nih.gov/pubmed/37416323
http://dx.doi.org/10.3389/fnagi.2023.1206123
_version_ 1785068423670136832
author Vandersteen, Clair
Plonka, Alexandra
Manera, Valeria
Sawchuk, Kim
Lafontaine, Constance
Galery, Kevin
Rouaud, Olivier
Bengaied, Nouha
Launay, Cyrille
Guérin, Olivier
Robert, Philippe
Allali, Gilles
Beauchet, Olivier
Gros, Auriane
author_facet Vandersteen, Clair
Plonka, Alexandra
Manera, Valeria
Sawchuk, Kim
Lafontaine, Constance
Galery, Kevin
Rouaud, Olivier
Bengaied, Nouha
Launay, Cyrille
Guérin, Olivier
Robert, Philippe
Allali, Gilles
Beauchet, Olivier
Gros, Auriane
author_sort Vandersteen, Clair
collection PubMed
description INTRODUCTION: The risk of developing Alzheimer's disease (AD) in older adults increasingly is being discussed in the literature on Post-Acute COVID-19 Syndrome (PACS). Remote digital Assessments for Preclinical AD (RAPAs) are becoming more important in screening for early AD, and should always be available for PACS patients, especially for patients at risk of AD. This systematic review examines the potential for using RAPA to identify impairments in PACS patients, scrutinizes the supporting evidence, and describes the recommendations of experts regarding their use. METHODS: We conducted a thorough search using the PubMed and Embase databases. Systematic reviews (with or without meta-analysis), narrative reviews, and observational studies that assessed patients with PACS on specific RAPAs were included. The RAPAs that were identified looked for impairments in olfactory, eye-tracking, graphical, speech and language, central auditory, or spatial navigation abilities. The recommendations' final grades were determined by evaluating the strength of the evidence and by having a consensus discussion about the results of the Delphi rounds among an international Delphi consensus panel called IMPACT, sponsored by the French National Research Agency. The consensus panel included 11 international experts from France, Switzerland, and Canada. RESULTS: Based on the available evidence, olfaction is the most long-lasting impairment found in PACS patients. However, while olfaction is the most prevalent impairment, expert consensus statements recommend that AD olfactory screening should not be used on patients with a history of PACS at this point in time. Experts recommend that olfactory screenings can only be recommended once those under study have reported full recovery. This is particularly important for the deployment of the olfactory identification subdimension. The expert assessment that more long-term studies are needed after a period of full recovery, suggests that this consensus statement requires an update in a few years. CONCLUSION: Based on available evidence, olfaction could be long-lasting in PACS patients. However, according to expert consensus statements, AD olfactory screening is not recommended for patients with a history of PACS until complete recovery has been confirmed in the literature, particularly for the identification sub-dimension. This consensus statement may require an update in a few years.
format Online
Article
Text
id pubmed-10320294
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103202942023-07-06 Alzheimer's early detection in post-acute COVID-19 syndrome: a systematic review and expert consensus on preclinical assessments Vandersteen, Clair Plonka, Alexandra Manera, Valeria Sawchuk, Kim Lafontaine, Constance Galery, Kevin Rouaud, Olivier Bengaied, Nouha Launay, Cyrille Guérin, Olivier Robert, Philippe Allali, Gilles Beauchet, Olivier Gros, Auriane Front Aging Neurosci Aging Neuroscience INTRODUCTION: The risk of developing Alzheimer's disease (AD) in older adults increasingly is being discussed in the literature on Post-Acute COVID-19 Syndrome (PACS). Remote digital Assessments for Preclinical AD (RAPAs) are becoming more important in screening for early AD, and should always be available for PACS patients, especially for patients at risk of AD. This systematic review examines the potential for using RAPA to identify impairments in PACS patients, scrutinizes the supporting evidence, and describes the recommendations of experts regarding their use. METHODS: We conducted a thorough search using the PubMed and Embase databases. Systematic reviews (with or without meta-analysis), narrative reviews, and observational studies that assessed patients with PACS on specific RAPAs were included. The RAPAs that were identified looked for impairments in olfactory, eye-tracking, graphical, speech and language, central auditory, or spatial navigation abilities. The recommendations' final grades were determined by evaluating the strength of the evidence and by having a consensus discussion about the results of the Delphi rounds among an international Delphi consensus panel called IMPACT, sponsored by the French National Research Agency. The consensus panel included 11 international experts from France, Switzerland, and Canada. RESULTS: Based on the available evidence, olfaction is the most long-lasting impairment found in PACS patients. However, while olfaction is the most prevalent impairment, expert consensus statements recommend that AD olfactory screening should not be used on patients with a history of PACS at this point in time. Experts recommend that olfactory screenings can only be recommended once those under study have reported full recovery. This is particularly important for the deployment of the olfactory identification subdimension. The expert assessment that more long-term studies are needed after a period of full recovery, suggests that this consensus statement requires an update in a few years. CONCLUSION: Based on available evidence, olfaction could be long-lasting in PACS patients. However, according to expert consensus statements, AD olfactory screening is not recommended for patients with a history of PACS until complete recovery has been confirmed in the literature, particularly for the identification sub-dimension. This consensus statement may require an update in a few years. Frontiers Media S.A. 2023-06-21 /pmc/articles/PMC10320294/ /pubmed/37416323 http://dx.doi.org/10.3389/fnagi.2023.1206123 Text en Copyright © 2023 Vandersteen, Plonka, Manera, Sawchuk, Lafontaine, Galery, Rouaud, Bengaied, Launay, Guérin, Robert, Allali, Beauchet and Gros. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Aging Neuroscience
Vandersteen, Clair
Plonka, Alexandra
Manera, Valeria
Sawchuk, Kim
Lafontaine, Constance
Galery, Kevin
Rouaud, Olivier
Bengaied, Nouha
Launay, Cyrille
Guérin, Olivier
Robert, Philippe
Allali, Gilles
Beauchet, Olivier
Gros, Auriane
Alzheimer's early detection in post-acute COVID-19 syndrome: a systematic review and expert consensus on preclinical assessments
title Alzheimer's early detection in post-acute COVID-19 syndrome: a systematic review and expert consensus on preclinical assessments
title_full Alzheimer's early detection in post-acute COVID-19 syndrome: a systematic review and expert consensus on preclinical assessments
title_fullStr Alzheimer's early detection in post-acute COVID-19 syndrome: a systematic review and expert consensus on preclinical assessments
title_full_unstemmed Alzheimer's early detection in post-acute COVID-19 syndrome: a systematic review and expert consensus on preclinical assessments
title_short Alzheimer's early detection in post-acute COVID-19 syndrome: a systematic review and expert consensus on preclinical assessments
title_sort alzheimer's early detection in post-acute covid-19 syndrome: a systematic review and expert consensus on preclinical assessments
topic Aging Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320294/
https://www.ncbi.nlm.nih.gov/pubmed/37416323
http://dx.doi.org/10.3389/fnagi.2023.1206123
work_keys_str_mv AT vandersteenclair alzheimersearlydetectioninpostacutecovid19syndromeasystematicreviewandexpertconsensusonpreclinicalassessments
AT plonkaalexandra alzheimersearlydetectioninpostacutecovid19syndromeasystematicreviewandexpertconsensusonpreclinicalassessments
AT maneravaleria alzheimersearlydetectioninpostacutecovid19syndromeasystematicreviewandexpertconsensusonpreclinicalassessments
AT sawchukkim alzheimersearlydetectioninpostacutecovid19syndromeasystematicreviewandexpertconsensusonpreclinicalassessments
AT lafontaineconstance alzheimersearlydetectioninpostacutecovid19syndromeasystematicreviewandexpertconsensusonpreclinicalassessments
AT galerykevin alzheimersearlydetectioninpostacutecovid19syndromeasystematicreviewandexpertconsensusonpreclinicalassessments
AT rouaudolivier alzheimersearlydetectioninpostacutecovid19syndromeasystematicreviewandexpertconsensusonpreclinicalassessments
AT bengaiednouha alzheimersearlydetectioninpostacutecovid19syndromeasystematicreviewandexpertconsensusonpreclinicalassessments
AT launaycyrille alzheimersearlydetectioninpostacutecovid19syndromeasystematicreviewandexpertconsensusonpreclinicalassessments
AT guerinolivier alzheimersearlydetectioninpostacutecovid19syndromeasystematicreviewandexpertconsensusonpreclinicalassessments
AT robertphilippe alzheimersearlydetectioninpostacutecovid19syndromeasystematicreviewandexpertconsensusonpreclinicalassessments
AT allaligilles alzheimersearlydetectioninpostacutecovid19syndromeasystematicreviewandexpertconsensusonpreclinicalassessments
AT beauchetolivier alzheimersearlydetectioninpostacutecovid19syndromeasystematicreviewandexpertconsensusonpreclinicalassessments
AT grosauriane alzheimersearlydetectioninpostacutecovid19syndromeasystematicreviewandexpertconsensusonpreclinicalassessments